Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-06EMA Authorised: Vumerity (Diroximel fumarate (BIIB098)) — Biogen Netherlands B.V.
EMA has authorised Vumerity (diroximel fumarate) for relapsing-remitting multiple sclerosis, expanding Biogen's portfolio in this indication…
-
EMA approval · 2026-07-03EMA Authorised: Kesimpta (ofatumumab) — Novartis Europharm Limited
Kesimpta (ofatumumab) has been authorised in the EU for Relapsing-Remitting Multiple Sclerosis.
-
EMA approval · 2026-06-11EMA Authorised: Teriflunomide Viatris (previously Teriflunomide Mylan) (teriflunomide) — Viatris Limited
Teriflunomide Viatris has been authorised in the EU for relapsing-remitting multiple sclerosis.
-
EMA approval · 2026-03-10EMA Authorised: Ponvory (ponesimod) — Laboratoires Juvisé Pharmaceuticals
The European Medicines Agency authorised Ponvory (ponesimod) for relapsing-remitting multiple sclerosis, with Laboratoires Juvisé Pharmaceut…
-
EMA approval · 2026-03-06EMA Authorised: Tyruko (natalizumab) — Sandoz GmbH
The European Medicines Agency authorised Tyruko, a natalizumab biosimilar by Sandoz GmbH, for treatment of multiple sclerosis including the …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-02EMA Authorised: Fingolimod Accord (fingolimod hydrochloride) — Accord Healthcare S.L.U.
The EMA authorised Fingolimod Accord (fingolimod hydrochloride) from Accord Healthcare S.L.U. for relapsing-remitting multiple sclerosis.
-
EMA approval · 2026-02-05EMA Authorised: Kesimpta (ofatumumab) — Novartis Europharm Limited
The European Medicines Agency authorised Kesimpta (ofatumumab) for Relapsing-Remitting Multiple Sclerosis, with Novartis Europharm Limited a…
-
EMA approval · 2025-12-11EMA Authorised: Teriflunomide Viatris (previously Teriflunomide Mylan) (teriflunomide) — Viatris Limited
The EMA authorised Teriflunomide Viatris for treatment of relapsing-relapsing multiple sclerosis, with Viatris Limited as the marketing auth…
-
EMA approval · 2025-11-28EMA Authorised: Fingolimod Mylan (Fingolimod) — Mylan Pharmaceuticals Limited
The European Medicines Agency authorised Fingolimod Mylan, a generic version of fingolimod, for relapsing-remitting multiple sclerosis.
-
EMA approval · 2025-10-08EMA Authorised: Briumvi (ublituximab) — Neuraxpharm Pharmaceuticals S.L.
The European Medicines Agency authorised Briumvi (ublituximab) for multiple sclerosis, including relapsing-remitting disease, with Neuraxpha…
-
EMA approval · 2025-09-25EMA Authorised: Riulvy (tegomil fumarate) — Neuraxpharm Pharmaceuticals S.L.
EMA authorised Riulvy (tegomil fumarate) for relapsing-remitting multiple sclerosis, with Neuraxpharm Pharmaceuticals S.L. as the marketing …
-
EMA approval · 2025-02-05EMA Authorised: Vumerity (Diroximel fumarate (BIIB098)) — Biogen Netherlands B.V.
EMA authorised Vumerity (diroximel fumarate) for relapsing-remitting multiple sclerosis, adding a new disease-modifying therapy to Biogen's …
-
FDA approval · 2022-11-16FDA Approved: VUMERITY — Supplemental Application (Biogen Inc.)
FDA approved Biogen's supplemental application for VUMERITY (diroximel fumarate).
-
FDA approval · 2020-01-10FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for OCREVUS (ocrelizumab) submitted by Genentech, Inc.
-
FDA approval · 2012-03-01FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GILENYA (fingolimod HCl) submitted by Novartis Pharmaceuticals Corporation, updating the pro…
-
FDA approval · 2009-10-26FDA Approved: KESIMPTA — Original Application (Novartis Pharmaceuticals Corporation)
The FDA approved Kesimpta (ofatumumab) under an original Biologics License Application from Novartis for the treatment of relapsing forms of…